Abstract
In the original version of this article (1), two instances of inadvertent duplication of crystal violet staining images occurred in Fig. 1D (control shRNA conditions in MDA-MB-468 and BT-20) and in Fig. 1F (0 mmol/L gefitinib control conditions in MDA-468 and BT-20). In addition, the same set of STAT3 Western blot bands was inadvertently duplicated in Fig. 3A (BT-20 and HCC1937). These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 362 |
| Number of pages | 1 |
| Journal | Cancer Research |
| Volume | 80 |
| Issue number | 2 |
| DOIs |
|
| State | Published - Jan 15 2020 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS